Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5
暂无分享,去创建一个
L. Lopalco | M. Clerici | S. Buttò | C. Pastori | P. Ferrante | M. Saresella | S. Declich | M. Fabiani | D. Trabattoni | G. Rizzardini | S. Piconi | C. Fracasso | M. Lukwiya
[1] C. Cheng‐Mayer,et al. Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.
[2] C. Brennan,et al. Serologic and phylogenetic characterization of HIV‐1 subtypes in Uganda , 1997, AIDS.
[3] C. Mackay,et al. Interleukin 10 Increases CCR5 Expression and HIV Infection in Human Monocytes , 1998, The Journal of experimental medicine.
[4] J. Albert,et al. REPLICATIVE CAPACITY OF HUMAN IMMUNODEFICIENCY VIRUS FROM PATIENTS WITH VARYING SEVERITY OF HIV INFECTION , 1986, The Lancet.
[5] J. Albert,et al. Dual effect of interleukin 4 on HIV-1 expression: implications for viral phenotypic switch and disease progression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[6] C. Mackay,et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[7] J. Albert,et al. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype , 1997, Journal of virology.
[8] J. Moore,et al. Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.
[9] T. Quinn,et al. Seroconversion rate, mortality, and clinical manifestations associated with the receipt of a human immunodeficiency virus-infected blood transfusion in Kinshasa, Zaire. , 1991, Journal of Infectious Diseases.
[10] B. Autran,et al. A Th0/Th2-like function of CD4+CD7- T helper cells from normal donors and HIV-infected patients. , 1995, Journal of immunology.
[11] R. Hayes,et al. Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV‐infected adults in Abidjan, Côte d'Ivoire , 1997, AIDS.
[12] Z. Bentwich,et al. Immune activation is a dominant factor in the pathogenesis of African AIDS. , 1995, Immunology today.
[13] C. Katlama,et al. CD4+CD7-CD57+ T cells: a new T-lymphocyte subset expanded during human immunodeficiency virus infection. , 1992, Blood.
[14] T. Quinn,et al. Human immunodeficiency virus infection among employees in an African hospital. , 1988, The New England journal of medicine.
[15] H. Schuitemaker,et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.
[16] P. Van de Perre. The epidemiology of HIV infection and AIDS in Africa. , 1995, Trends in microbiology.
[17] A. Trkola,et al. Genetic Subtype-Independent Inhibition of Human Immunodeficiency Virus Type 1 Replication by CC and CXC Chemokines , 1998, Journal of Virology.
[18] J. Albert,et al. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1. , 1998, Virology.
[19] N. Nagelkerke,et al. Comparison of the declines in CD4 counts in HIV-1-seropositive female sex workers and women from the general population in Nairobi, Kenya. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[20] H. Schuitemaker,et al. Infectious Cellular Load in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals and Susceptibility of Peripheral Blood Mononuclear Cells from Their Exposed Partners to Non-Syncytium-Inducing HIV-1 as Major Determinants for HIV-1 Transmission in Homosexual Couples , 1998, Journal of Virology.
[21] M. Baggiolini,et al. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes , 1996, The Journal of experimental medicine.
[22] M. Wilkes,et al. Health News Reporting: Reply , 1997, Annals of Internal Medicine.
[23] H. Schuitemaker,et al. Association between CCR5 Genotype and the Clinical Course of HIV-1 Infection , 1997, Annals of Internal Medicine.
[24] M. Moroni,et al. Human immunodeficiency virus (HIV) phenotype and interleukin-2/ interleukin-10 ratio are associated markers of protection and progression in HIV infection. , 1996, Blood.
[25] Characterization,et al. Syncytium-inducing and non-syncytium-inducing capacity of human immunodeficiency virus type 1 subtypes other than B: phenotypic and genotypic characteristics. WHO Network for HIV Isolation and Characterization. , 1994, AIDS research and human retroviruses.
[26] Z. Bentwich,et al. Increased CCR5 expression with decreased beta chemokine secretion in Ethiopians: relevance to AIDS in Africa. , 1999, Journal of human virology.
[27] Z. Bentwich,et al. Pathogenesis of AIDS in Africa - Lessons from the Ethiopian immigrants in Israel , 1997 .
[28] J. Hoxie,et al. Evidence that Antibody-Mediated Neutralization of Human Immunodeficiency Virus Type 1 by Sera from Infected Individuals Is Independent of Coreceptor Usage , 1998, Journal of Virology.
[29] M. Clerici,et al. Immunological activation markers in the serum of African and European HIV‐seropositive and seronegative individuals , 1996, AIDS.
[30] P. Ferrante,et al. Immune activation in HIV‐infected African individuals , 1998 .
[31] A. Grant,et al. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. , 1997, AIDS.
[32] S. Zolla-Pazner,et al. Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage , 1998, Journal of Virology.
[33] T. F. Rinke de Wit,et al. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. , 1999, AIDS.
[34] F. Brun-Vézinet,et al. Genetic diversity and HIV detection by polymerase chain reaction , 1995, The Lancet.
[35] J. Albert,et al. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection , 1994, Journal of clinical microbiology.
[36] J. Andersson,et al. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. , 1998, The American journal of pathology.
[37] A. Trkola,et al. Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents Is Independent of Coreceptor Usage , 1998, Journal of Virology.
[38] R. Lal,et al. Adaptation to promiscuous usage of CC and CXC‐chemokine coreceptors in vivo correlates with HIV‐1 disease progression , 1998, AIDS.
[39] M. Bakari,et al. Survival time of patients with acquired immune deficiency syndrome: experience with 274 patients in Dar-es-Salaam. , 1990, East African medical journal.